Buscar
Mostrando ítems 1-10 de 145
Impact on overall survival and disease-free survival of adjuvant chemotherapy after neoadjuvant chemoradiotherapy for rectal cancer
(Amer Soc Clinical Oncology, 2012-05-20)
Impact on overall survival and disease-free survival of adjuvant chemotherapy after neoadjuvant chemoradiotherapy for rectal cancer
(Amer Soc Clinical Oncology, 2012-05-20)
Concurrent chemoradiotherapy with weekly paclitaxel in malignant cerebral glioma treatment
(KARGER, 2008)
Background: Anaplastic astrocytomas (AA) and glioblastomas (GB) are the most common malignant gliomas, and despite newly developed drugs and combined treatments, they still have an adverse prognosis. Paclitaxel is a cytotoxic ...
Plasma Osteopontin Levels in Patients With Head and Neck Cancer Undergoing Chemoradiotherapy
(AMER MEDICAL ASSOC, 2009)
Objectives: To explore the prognostic role of plasma levels of osteopontin (OPN), a phosphoglycoprotein with adhesive properties, in patients with head and neck squamous cell carcinoma (HNSCC) undergoing concomitant ...
Adjuvant chemoradiotherapy in advanced gastric cancer. Experience in 168 patients Radioquimioterapia adyuvante en cáncer gástrico completamente resecado: Experiencia del Instituto Nacional del Cáncer de Chile
(Sociedad Medica de Santiago, 2014)
Background: Gastric cancer is one of the most lethal tumors in the Chilean population. Aim: To report the results of adjuvant chemoradiotherapy in advanced gastric cancer. Material and Methods: Review of medical records ...
The Role of Carcinoembriogenic Antigen in Predicting Response and Survival to Neoadjuvant Chemoradiotherapy for Distal Rectal Cancer
(LIPPINCOTT WILLIAMS & WILKINS, 2009)
PURPOSE: Carcinoembriogenic antigen (CEA) is the most frequently used tumor marker in rectal cancer. A decrease in carcinoembriogenic antigen after radical surgery is associated with survival in these patients. Neoadjuvant ...
Pre-existing tumoral B cell infiltration and impaired genome maintenance correlate with response to chemoradiotherapy in locally advanced rectal cancer
(MDPI AG, 2020-08)
Locally advanced rectal cancer (LARC) remains a medical challenge. Reliable biomarkers to predict which patients will significantly respond to neoadjuvant chemoradiotherapy (nCRT) have not been identified. We evaluated ...